ST. LOUIS, Sept. 27 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) is pleased to announce that Patrick M. Sullivan has been named the Vice President of R&D for the Research Biotech business unit, effective October 1, 2007. In this role, he will help expand Sigma-Aldrich's leadership position through the development of new and innovative products for life science researchers. Sullivan has been involved with Sigma-Aldrich since 2005 as a member of the Company's Scientific Advisory Board, where he provided a large pharmaceutical perspective on new strategic plans and product offerings in the Company's Research Biotech business unit. Sullivan will report directly to David A. Smoller, Ph.D., President of Research Biotech.
Pat Sullivan has over 19 years of experience using and developing genomic-based solutions for the pharmaceutical and biotech industries. He was employed by Monsanto/Searle/Pharmacia for 12 years, where he provided molecular biology support for Inflammation and angiogenesis new target/biomarker discovery projects. He joined Incyte Genomics in 2000 as the Vice President of Global Operations, responsible for managing all genomic products and services. Most recently, Sullivan was employed by Pfizer, where he led efforts to identify new therapeutic opportunities in osteoarthritis and cardiovascular diseases.
"We are pleased to have such an strong and experienced leader join our organization," said David A. Smoller. "Patrick's combination of technical expertise, strong ability to analyze complex business operations and implement strategies to improve performance will be an immediate asset to our Research Biotech business unit's mission of bringing innovative technologies and solutions to life science researchers. We look forward to having him join us in making these valuable contributions to our life science community."
Sullivan received his B.S. degree in Microbiology from Western Illinois University and his M.S. degree in Molecular Biology from Southern Illinois University.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,700 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at sigma-aldrich.com.
Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Company's operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.
Copyright©2007 PR Newswire.
All rights reserved